Electra Therapeutics Q3 2026 Results: Net Loss of $23.9M, Loss Widens
Electra Therapeutics is a clinical-stage biotechnology company focused on SIRP-targeted therapies, specifically its lead candidates ipsoprubart and ELA822. As of November 2026, the company remains pre-revenue with significant operating losses and expects to require substantial additional capital to fund its research and development programs.
- Key figure
- Net loss $23.9M